BTK and B-cell chronic lymphocytic leukemia: In the era of second-generation BTK inhibitors, which seem to induce less frequently cardiotoxicity than the first generation (St-Pierre and Ma, 2022), our findings suggest the need to move towards a better management of ibrutinib-related CV events in the setting of therapy optimization, especially for elderly and frail patients affected by CLL.